BackAnnovis Bio Overview

Annovis Bio Other Assets

Latest other assets for ANVS: $2B.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$2.02B
↓ 55.02% YoYΔ $-2.48B vs prior year quarter

Peer average / median

Loading

Annovis Bio Other Assets History

Loading

Annovis Bio vs. peers: Other Assets Comparison

Loading

Annovis Bio Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Annovis Bio (ANVS) FAQ

As of the most recent data (March 2026), ANVS shows a other assets of $2B. That compares with $4.5B in the prior-year period — down 55.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANVS's other assets is now $2B (was $4.5B) — a 55.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Annovis Bio is outperforming or lagging.

Tracking ANVS's other assets over time shows whether Annovis Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $2B That compares with $4.5B in the prior-year period — down 55.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Annovis Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $2B) with ownership activity and broader fundamentals.

Annovis Bio's other assets is $2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.